{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Positive+Solid+Tumor&page=3", "query": { "condition": "HER2-Positive Solid Tumor", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 102, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Positive+Solid+Tumor&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Positive+Solid+Tumor&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T14:28:34.336Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT03284723", "title": "PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "PF-06804103", "type": "DRUG" }, { "name": "PF-06804103 + Palbociclib +Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2017-11-01", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 26, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03284723" }, { "nct_id": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Hematologic Neoplasms", "Ovarian Cancer", "HER2-positive Advanced Solid Tumors", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Cervical Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "tebotelimab 1 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 3 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 10 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 30 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 120 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 300 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 400 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 600 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 800 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 1200 mg", "type": "BIOLOGICAL" }, { "name": "margetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2017-08-18", "completion_date": "2023-02-08", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219268" }, { "nct_id": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Small Cell Lung Cancer", "Ovarian Cancer", "Gastric Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Advanced Solid Tumor", "Endometrial Cancer", "Prostate Cancer", "TNBC - Triple-Negative Breast Cancer", "GastroEsophageal Cancer", "Bladder Cancer" ], "interventions": [ { "name": "BG-68501", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2024-03-11", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 6, "location_summary": "Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257264" }, { "nct_id": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Solid Tumor", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "ACE1702", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acepodia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-24", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 2, "location_summary": "Chicago, Illinois • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04319757" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT05546268", "title": "Study of Oral MRT-2359 in Selected Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "SCLC", "High Grade Neuroendocrine Cancer", "DLBCL", "L-MYC and N-MYC Amplified Solid Tumors", "NSCLC With High or Low L-MYC or N-MYC Expression", "HR-positive, HER2-negative Breast Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Oral MRT-2359", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Monte Rosa Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2022-10-12", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lawrence", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05546268" }, { "nct_id": "NCT03725436", "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "TP53 wt Allele", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "MDM2/MDMX Inhibitor ALRN-6924", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-01-24", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725436" }, { "nct_id": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 582, "start_date": "2013-09-30", "completion_date": "2023-01-02", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01953926" }, { "nct_id": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Bladder Cancer", "HER2-positive Solid Tumor" ], "interventions": [ { "name": "PRS-343 in Combination with Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-08-21", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-09T14:28:34.336Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650348" } ] }